Vinva Investment Management Ltd Has $3.93 Million Stake in Becton, Dickinson and Company $BDX

Vinva Investment Management Ltd grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 26.1% in the 3rd quarter, Holdings Channel reports. The fund owned 21,377 shares of the medical instruments supplier’s stock after purchasing an additional 4,423 shares during the quarter. Vinva Investment Management Ltd’s holdings in Becton, Dickinson and Company were worth $3,933,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BDX. Vanguard Group Inc. increased its stake in Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after purchasing an additional 147,041 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 13.8% in the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after buying an additional 1,208,218 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock valued at $1,712,715,000 after buying an additional 636,138 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.8% in the second quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier’s stock valued at $1,153,157,000 after buying an additional 244,199 shares during the period. Finally, Norges Bank bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $653,377,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several research reports. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Royal Bank Of Canada set a $172.00 price target on Becton, Dickinson and Company in a report on Tuesday, February 10th. TD Cowen upped their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Finally, Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $167.31 on Monday. The stock has a market capitalization of $47.64 billion, a price-to-earnings ratio of 27.29, a PEG ratio of 12.12 and a beta of 0.24. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The firm has a fifty day simple moving average of $193.26 and a 200 day simple moving average of $191.16. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same period in the previous year, the business earned $3.43 EPS. The company’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,416 shares of company stock worth $674,693 in the last quarter. 0.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.